Valvular & structural heart diseaseCohort study
Clinical Outcomes of Transfemoral Transcatheter Mitral Valve Replacement
- Registry study
- international
- multicentre (41 centres)
Authors' conclusion
TMVR using dedicated TF devices demonstrates favorable safety, durable MR reduction, and sustained functional improvement in high-risk patients.
Study context
- Population
- Patients with mitral regurgitation (MR) undergoing transfemoral (TF) transcatheter mitral valve replacement (TMVR) with dedicated devices (CHOICE-MI Registry)9 different devices
- Participants
- 124 patients
- Outcome
- All-cause mortality or HF hospitalization
- Follow-up
- Up to 2 years
Main finding
As reported in the abstract
Primary endpoint rate at 2 years
52.4% (95% CI: 40.2%-62.1%)
Observational data: associations, not effects.
Further findings
All-cause mortality or HF hospitalization · 1 year
- Primary endpoint rate at 1 year
- 44.1% (95% CI: 30.6%-50.0%)
CV mortality · 1 and 2 years
- CV mortality at 1 year
- 14.7% (95% CI: 7.9%-21.5%)
- CV mortality at 2 years
- 20.3% (95% CI: 11.4%-29.1%)
Technical success
- Technical success
- 113 of 124 patients (91.1%)
Residual MR ≤1+ · discharge
- Residual MR ≤1+ at discharge, stable at follow-up
- 94.9%
NYHA functional class · 1 and 2 years
- NYHA class significantly improved at 1- and 2-year follow-up
Predictors
- AF independent predictor of the primary endpoint; technical success associated with survival
Original publication
Clinical Outcomes of Transfemoral Transcatheter Mitral Valve Replacement. JACC Cardiovasc Interv. Published 20 May 2026. doi:10.1016/j.jcin.2026.05.003
Summarised from the published abstract; every number is checked against it